Do	O
polymorphisms	O
in	O
MDR1	B:C0376622
and	O
CYP3A5	O
genes	I:C1413882
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
on	O
imatinib	O
therapy	O
?.	O

Do	O
polymorphisms	O
in	O
MDR1	O
and	O
CYP3A5	B:C1413882
genes	I:C1413882
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
on	O
imatinib	O
therapy	O
?.	O

Do	O
polymorphisms	O
in	O
MDR1	O
and	O
CYP3A5	O
genes	I:C1413882
influence	O
the	O
risk	O
of	O
cytogenetic	B:C0920028
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
on	O
imatinib	O
therapy	O
?.	O

Do	O
polymorphisms	O
in	O
MDR1	O
and	O
CYP3A5	O
genes	I:C1413882
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	B:C0023473
myeloid	I:C0023473
leukemia	I:C0023473
on	O
imatinib	O
therapy	O
?.	O

Do	O
polymorphisms	O
in	O
MDR1	O
and	O
CYP3A5	O
genes	I:C1413882
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
on	O
imatinib	B:C0935989
therapy	O
?.	O

Do	O
polymorphisms	O
in	O
MDR1	O
and	O
CYP3A5	O
genes	I:C1413882
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
on	O
imatinib	O
therapy	B:C0087111
?.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	B:C0314627
coding	I:C0314627
for	O
imatinib	O
transporters	O
and	O
metabolizing	O
enzymes	I:C0014442
on	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
(	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
)	O
is	O
not	O
known	O
.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	O
coding	I:C0314627
for	O
imatinib	B:C0935989
transporters	O
and	O
metabolizing	O
enzymes	I:C0014442
on	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
(	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
)	O
is	O
not	O
known	O
.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	O
coding	I:C0314627
for	O
imatinib	O
transporters	B:C0007292
and	O
metabolizing	O
enzymes	I:C0014442
on	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
(	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
)	O
is	O
not	O
known	O
.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	O
coding	I:C0314627
for	O
imatinib	O
transporters	O
and	O
metabolizing	B:C0014442
enzymes	I:C0014442
on	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
(	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
)	O
is	O
not	O
known	O
.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	O
coding	I:C0314627
for	O
imatinib	O
transporters	O
and	O
metabolizing	O
enzymes	I:C0014442
on	O
cytogenetic	B:C0920028
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
(	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
)	O
is	O
not	O
known	O
.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	O
coding	I:C0314627
for	O
imatinib	O
transporters	O
and	O
metabolizing	O
enzymes	I:C0014442
on	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	B:C0023473
myeloid	I:C0023473
leukemia	I:C0023473
(	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
)	O
is	O
not	O
known	O
.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	O
coding	I:C0314627
for	O
imatinib	O
transporters	O
and	O
metabolizing	O
enzymes	I:C0014442
on	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
(	O
chronic	B:C0023473
myeloid	I:C0023473
leukemia	I:C0023473
)	O
is	O
not	O
known	O
.	O

One	O
hundred	O
and	O
four	O
patients	O
(	O
52	O
cases	O
with	O
cytogenetic	B:C0920028
relapse	I:C0920028
and	O
52	O
controls	O
without	O
relapse	O
)	O
with	O
chronic	O
-	I:C0023473
phase	I:C0023473
CML	I:C0023473
on	O
imatinib	O
therapy	O
and	O
have	O
completed	O
5	O
years	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
were	O
enrolled	O
.	O

One	O
hundred	O
and	O
four	O
patients	O
(	O
52	O
cases	O
with	O
cytogenetic	O
relapse	I:C0920028
and	O
52	O
controls	O
without	O
relapse	O
)	O
with	O
chronic	B:C0023473
-	I:C0023473
phase	I:C0023473
CML	I:C0023473
on	O
imatinib	O
therapy	O
and	O
have	O
completed	O
5	O
years	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
were	O
enrolled	O
.	O

One	O
hundred	O
and	O
four	O
patients	O
(	O
52	O
cases	O
with	O
cytogenetic	O
relapse	I:C0920028
and	O
52	O
controls	O
without	O
relapse	O
)	O
with	O
chronic	O
-	I:C0023473
phase	I:C0023473
CML	I:C0023473
on	O
imatinib	B:C0935989
therapy	O
and	O
have	O
completed	O
5	O
years	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
were	O
enrolled	O
.	O

One	O
hundred	O
and	O
four	O
patients	O
(	O
52	O
cases	O
with	O
cytogenetic	O
relapse	I:C0920028
and	O
52	O
controls	O
without	O
relapse	O
)	O
with	O
chronic	O
-	I:C0023473
phase	I:C0023473
CML	I:C0023473
on	O
imatinib	O
therapy	B:C0087111
and	O
have	O
completed	O
5	O
years	O
of	O
follow	O
-	I:C1522577
up	I:C1522577
were	O
enrolled	O
.	O

One	O
hundred	O
and	O
four	O
patients	O
(	O
52	O
cases	O
with	O
cytogenetic	O
relapse	I:C0920028
and	O
52	O
controls	O
without	O
relapse	O
)	O
with	O
chronic	O
-	I:C0023473
phase	I:C0023473
CML	I:C0023473
on	O
imatinib	O
therapy	O
and	O
have	O
completed	O
5	O
years	O
of	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
were	O
enrolled	O
.	O

The	O
following	O
single	B:C0752046
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	B:C0752046
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	B:C1285573
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	B:C0314659
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	B:C0314659
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	B:C0314659
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	B:C0314659
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	B:C0376622
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	B:C0314659
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	B:C1413882
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	B:C3714764
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	O
sequencing	I:C1294197
.	O

The	O
following	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphisms	I:C0752046
)	O
were	O
genotyped	O
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	I:C0376622
and	O
A6986G	O
in	O
CYP3A5	O
gene	I:C1413882
,	O
using	O
PCR	O
-	I:C3714764
RFLP	I:C3714764
method	I:C3714764
and	O
validated	O
by	O
direct	O
gene	B:C1294197
sequencing	I:C1294197
.	O

Imatinib	B:C0935989
trough	O
levels	O
were	O
measured	O
using	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	O
.	O

Imatinib	O
trough	O
levels	O
were	O
measured	O
using	O
LC	B:C0872318
-	I:C0872318
MS	I:C0872318
/	O
MS	O
.	O

Imatinib	O
trough	O
levels	O
were	O
measured	O
using	O
LC	O
-	I:C0872318
MS	I:C0872318
/	O
MS	B:C0037813
.	O

Patients	O
with	O
CC	O
genotype	O
for	O
MDR1	B:C0376622
-	O
C1236T	O
polymorphism	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
cytogenetic	O
relapse	I:C0920028
[	O
OR	O
=4.382	O
,	O
95	O
%	O
CI	O
(	O
1.145	O
,	O
16.774	O
)	O
,	O
p	O
=	O
.022	O
]	O
,	O
while	O
those	O
with	O
TT	O
genotype	O
for	O
MDR1	O
-	O
C3435T	O
polymorphism	O
had	O
significantly	O
lower	O
risk	O
of	O
relapse	O
[	O
OR	O
=0.309	O
,	O
95	O
%	O
CI	O
(	O
0.134	O
,	O
0.708	O
)	O
,	O
p	O
=	O
.005	O
]	O
.	O

Patients	O
with	O
CC	O
genotype	O
for	O
MDR1	O
-	O
C1236T	B:C0314659
polymorphism	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
cytogenetic	O
relapse	I:C0920028
[	O
OR	O
=4.382	O
,	O
95	O
%	O
CI	O
(	O
1.145	O
,	O
16.774	O
)	O
,	O
p	O
=	O
.022	O
]	O
,	O
while	O
those	O
with	O
TT	O
genotype	O
for	O
MDR1	O
-	O
C3435T	O
polymorphism	O
had	O
significantly	O
lower	O
risk	O
of	O
relapse	O
[	O
OR	O
=0.309	O
,	O
95	O
%	O
CI	O
(	O
0.134	O
,	O
0.708	O
)	O
,	O
p	O
=	O
.005	O
]	O
.	O

Patients	O
with	O
CC	O
genotype	O
for	O
MDR1	O
-	O
C1236T	O
polymorphism	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
cytogenetic	B:C0920028
relapse	I:C0920028
[	O
OR	O
=4.382	O
,	O
95	O
%	O
CI	O
(	O
1.145	O
,	O
16.774	O
)	O
,	O
p	O
=	O
.022	O
]	O
,	O
while	O
those	O
with	O
TT	O
genotype	O
for	O
MDR1	O
-	O
C3435T	O
polymorphism	O
had	O
significantly	O
lower	O
risk	O
of	O
relapse	O
[	O
OR	O
=0.309	O
,	O
95	O
%	O
CI	O
(	O
0.134	O
,	O
0.708	O
)	O
,	O
p	O
=	O
.005	O
]	O
.	O

Patients	O
with	O
CC	O
genotype	O
for	O
MDR1	O
-	O
C1236T	O
polymorphism	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
cytogenetic	O
relapse	I:C0920028
[	O
OR	O
=4.382	O
,	O
95	O
%	O
CI	O
(	O
1.145	O
,	O
16.774	O
)	O
,	O
p	O
=	O
.022	O
]	O
,	O
while	O
those	O
with	O
TT	O
genotype	O
for	O
MDR1	B:C0376622
-	O
C3435T	O
polymorphism	O
had	O
significantly	O
lower	O
risk	O
of	O
relapse	O
[	O
OR	O
=0.309	O
,	O
95	O
%	O
CI	O
(	O
0.134	O
,	O
0.708	O
)	O
,	O
p	O
=	O
.005	O
]	O
.	O

Patients	O
with	O
CC	O
genotype	O
for	O
MDR1	O
-	O
C1236T	O
polymorphism	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
cytogenetic	O
relapse	I:C0920028
[	O
OR	O
=4.382	O
,	O
95	O
%	O
CI	O
(	O
1.145	O
,	O
16.774	O
)	O
,	O
p	O
=	O
.022	O
]	O
,	O
while	O
those	O
with	O
TT	O
genotype	O
for	O
MDR1	O
-	O
C3435T	B:C0314659
polymorphism	O
had	O
significantly	O
lower	O
risk	O
of	O
relapse	O
[	O
OR	O
=0.309	O
,	O
95	O
%	O
CI	O
(	O
0.134	O
,	O
0.708	O
)	O
,	O
p	O
=	O
.005	O
]	O
.	O

Patients	O
with	O
CC	O
genotype	O
for	O
MDR1	O
-	O
C1236T	O
polymorphism	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
cytogenetic	O
relapse	I:C0920028
[	O
OR	O
=4.382	O
,	O
95	O
%	O
CI	O
(	O
1.145	O
,	O
16.774	O
)	O
,	O
p	O
=	O
.022	O
]	O
,	O
while	O
those	O
with	O
TT	O
genotype	O
for	O
MDR1	O
-	O
C3435T	O
polymorphism	O
had	O
significantly	O
lower	O
risk	O
of	O
relapse	B:C0920028
[	O
OR	O
=0.309	O
,	O
95	O
%	O
CI	O
(	O
0.134	O
,	O
0.708	O
)	O
,	O
p	O
=	O
.005	O
]	O
.	O

Imatinib	B:C0935989
trough	O
levels	O
were	O
lower	O
in	O
patients	O
with	O
relapse	O
compared	O
to	O
those	O
without	O
relapse	O
(	O
1551.4	O
±	O
1324.1	O
vs.	O
2154.2	O
±	O
1358.3	O
ng/mL	O
;	O
p	O
=	O
.041	O
)	O
.	O

Imatinib	O
trough	O
levels	O
were	O
lower	O
in	O
patients	O
with	O
relapse	B:C0920028
compared	O
to	O
those	O
without	O
relapse	O
(	O
1551.4	O
±	O
1324.1	O
vs.	O
2154.2	O
±	O
1358.3	O
ng/mL	O
;	O
p	O
=	O
.041	O
)	O
.	O

Imatinib	O
trough	O
levels	O
were	O
lower	O
in	O
patients	O
with	O
relapse	O
compared	O
to	O
those	O
without	O
relapse	B:C0920028
(	O
1551.4	O
±	O
1324.1	O
vs.	O
2154.2	O
±	O
1358.3	O
ng/mL	O
;	O
p	O
=	O
.041	O
)	O
.	O

MDR1	B:C0376622
-	O
C3435T	O
genotype	O
[	O
adjusted	O
-	O
OR	O
:	O
0.266	O
;	O
95	O
%	O
CI	O
(	O
0.111	O
,	O
0.636	O
)	O
;	O
p	O
=	O
.003	O
]	O
and	O
trough	O
levels	O
(	O
p	O
=	O
.014	O
)	O
were	O
independent	O
predictors	O
of	O
relapse	O
in	O
multivariate	O
analysis	O
.	O

MDR1	O
-	O
C3435T	B:C0314659
genotype	O
[	O
adjusted	O
-	O
OR	O
:	O
0.266	O
;	O
95	O
%	O
CI	O
(	O
0.111	O
,	O
0.636	O
)	O
;	O
p	O
=	O
.003	O
]	O
and	O
trough	O
levels	O
(	O
p	O
=	O
.014	O
)	O
were	O
independent	O
predictors	O
of	O
relapse	O
in	O
multivariate	O
analysis	O
.	O

MDR1	O
-	O
C3435T	O
genotype	O
[	O
adjusted	O
-	O
OR	O
:	O
0.266	O
;	O
95	O
%	O
CI	O
(	O
0.111	O
,	O
0.636	O
)	O
;	O
p	O
=	O
.003	O
]	O
and	O
trough	O
levels	O
(	O
p	O
=	O
.014	O
)	O
were	O
independent	O
predictors	O
of	O
relapse	B:C0920028
in	O
multivariate	O
analysis	O
.	O

To	O
conclude	O
,	O
C1236T	B:C0314659
and	O
C3435T	O
polymorphisms	O
in	O
MDR1	O
gene	I:C0376622
and	O
trough	O
levels	O
significantly	O
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
.	O

To	O
conclude	O
,	O
C1236T	O
and	O
C3435T	B:C0314659
polymorphisms	O
in	O
MDR1	O
gene	I:C0376622
and	O
trough	O
levels	O
significantly	O
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
.	O

To	O
conclude	O
,	O
C1236T	O
and	O
C3435T	O
polymorphisms	O
in	O
MDR1	B:C0376622
gene	I:C0376622
and	O
trough	O
levels	O
significantly	O
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
.	O

To	O
conclude	O
,	O
C1236T	O
and	O
C3435T	O
polymorphisms	O
in	O
MDR1	O
gene	I:C0376622
and	O
trough	O
levels	O
significantly	O
influence	O
the	O
risk	O
of	O
cytogenetic	B:C0920028
relapse	I:C0920028
.	O

MDR1	B:C0376622
-	O
C3435T	O
genotype	O
might	O
emerge	O
as	O
a	O
potential	O
biomarker	O
to	O
predict	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
.	O

MDR1	O
-	O
C3435T	B:C0314659
genotype	O
might	O
emerge	O
as	O
a	O
potential	O
biomarker	O
to	O
predict	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
.	O

MDR1	O
-	O
C3435T	O
genotype	O
might	O
emerge	O
as	O
a	O
potential	O
biomarker	B:C0005516
to	O
predict	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
.	O

MDR1	O
-	O
C3435T	O
genotype	O
might	O
emerge	O
as	O
a	O
potential	O
biomarker	O
to	O
predict	O
the	O
risk	O
of	O
cytogenetic	B:C0920028
relapse	I:C0920028
in	O
patients	O
with	O
chronic	O
myeloid	I:C0023473
leukemia	I:C0023473
.	O

MDR1	O
-	O
C3435T	O
genotype	O
might	O
emerge	O
as	O
a	O
potential	O
biomarker	O
to	O
predict	O
the	O
risk	O
of	O
cytogenetic	O
relapse	I:C0920028
in	O
patients	O
with	O
chronic	B:C0023473
myeloid	I:C0023473
leukemia	I:C0023473
.	O

